Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€87.93

€87.93

0.210%
0.18
0.210%
€110.00
 
15:26 / Tradegate WKN: 920657 / Name: Snof / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...
Your prediction

Sanofi S.A. Stock

Sanofi S.A. gained 0.210% compared to yesterday.
The community is currently still undecided about Sanofi S.A. with 1 Buy predictions and 0 Sell predictions.
As a result the target price of 110 € shows a positive potential of 25.1% compared to the current price of 87.93 € for Sanofi S.A..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Sanofi S.A. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Sanofi S.A. in the next few years

Pros
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Sanofi S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sanofi S.A. 0.210% -4.308% -9.049% -2.835% -6.220% -12.460% -0.645%
Ipsen S.A. 0.390% 1.566% -0.575% -15.610% -5.978% 10.016% 43.568%
Johnson & Johnson 1.150% -0.178% -1.985% 0.074% -3.408% -18.364% 2.974%
Elanco Animal Health Inc. -1.610% -1.477% 37.705% -30.839% 1.645% -48.211% -44.632%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financials of Snof, a notable player in the pharmaceuticals industry under the US symbol, reveal a company that is navigating the complexities of the market with a significant degree of stability. At first glance, the metrics suggest that Snof is maintaining a solid financial position, showcasing steady revenue growth and robust earnings, while also investing heavily in research and development. However, a deeper dive into specific figures illustrates both strengths and weaknesses that can help shape expectations for potential investors or stakeholders.

Strong Revenue Generation: For the fiscal year ending December 31, 2023, Snof reported total revenues of approximately €43.07 billion. This sizable revenue indicates robust demand for its pharmaceutical products and the effectiveness of its sales strategy, especially considering the revenue reflected a continued upward trend from previous years.

Solid Profit Margins: The profit margin stands at approximately 8.95%, which suggests that Snof is not only generating revenue but also retaining a healthy portion as profit. This profitability is further emphasized by a stable operating margin of 14.11%, making it clear that operational efficiency is being managed well.

Comments

Prediction Buy
Perf. (%) 1.76%
Target price 95.000
Change
Ends at 06.02.23

Buy with target price 95.0
Show more

Prediction Buy
Perf. (%) 20.12%
Target price 89.000
Change
Ends at 14.09.22

Buy with target price 89.0
Show more

Prediction Sell
Perf. (%) 9.12%
Target price
Change
Ends at 20.12.19

Sell beendet
Show more

News

Sanofi Stock: $9.1 Billion Blueprint Deal Sparks Debate
Sanofi Stock: $9.1 Billion Blueprint Deal Sparks Debate

The French pharmaceutical giant Sanofi has announced plans to acquire US-based Blueprint Medicines for $9.1 billion, marking a strategic push into the specialized immunology market. The ambitious

Sanofi Stock: Setback in Lung Drug Trial Hits Shares
Sanofi Stock: Setback in Lung Drug Trial Hits Shares

The French pharmaceutical giant Sanofi faced a significant blow as its lung medication candidate Itepekimab delivered mixed Phase III trial results. While one of the critical studies showed the drug

Sanofi Stock: $600M Alzheimer Drug Acquisition Bet
Sanofi Stock: $600M Alzheimer Drug Acquisition Bet

Sanofi has made a strategic move to strengthen its neurology portfolio by acquiring Vigil Neuroscience for up to $600 million. The French pharmaceutical giant will pay $470 million ($8 per share)